[Matrix metalloproteinase inhibitors].
Nakajima
M
M
Novartis Pharma K. K., Research, Okubo, Tsukuba, Japan. motowo.nakajima@pharma.novartis.com
D000818:Animals; D000970:Antineoplastic Agents; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000502:physiology; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009930:Organic Chemicals; D010649:Phenylalanine / Q000031:analogs & derivatives; D013876:Thiophenes
D000970:Antineoplastic Agents; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors; D009930:Organic Chemicals; D013876:Thiophenes; C113282:prinomastat; D010649:Phenylalanine; C080985:batimastat; C100342:marimastat; D020782:Matrix Metalloproteinases